Search Videos and More
Course
New Directions in the Diagnosis and Treatment of Hematologic Cancers
DATE: Tuesday, April 16, 2024
News
Inspiring Residents to Climb Higher
When asked why he chose Fox Chase Cancer Center for his urologic surgery fellowship (2019-2021), Marshall Strother, MD, responds, “I liked the way ‘Fox,’ as he calls Fox Chase, has an exacting, intentional, and deliberate method of training. Hierarchies are flattened there, allowing new surgeons to work and learn with the most experienced on the team.”
News
Recognizing International Excellence
Fox Chase Cancer Center is known around the world as an international leader in bold urologic cancer care, scientific research, translational research, and education. These are the people whose accomplishments make it happen.
News
Adstiladrin (Nadofaragene Firadenovec-vncg): The First Intravesical Gene Therapy for Bladder Cancer Now Available at Fox Chase
Eligible patients will now have access to the first FDA-approved intravesical gene therapy for non-muscle invasive bladder cancer (NMIBC) at Fox Chase Cancer Center.
News
Meet the Navigators to Complex, Coordinated, Compassionate Genitourinary Cancer Care
A prostate, kidney, or bladder cancer diagnosis can turn someone’s world upside down. If this weren’t enough, now the patient has an additional burden of coordinating medical appointments, scheduling tests, and gathering biopsy results from other hospitals.
Course
2024 Atlantic Regional Hematopathology Meeting
Advancements in hematopathology based on molecular and genetic information are rapidly evolving, making it challenging to keep up with the latest developments and their implications for diagnosis and therapy. This meeting will focus on the role of molecular pathology and new technologies in diagnosis, prognostic stratification, and treatment of complex cases. Participants will gain insights into the significant changes, revisions, and new categories in the 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors. Renowned invited pathologists and senior authors of the new WHO edition, Dr. Joseph Khoury, Dr. German Ott, and Dr. Sanam Loghavi, will discuss notable updates, modifications, and new classifications in the morphology and molecular genetics of hematologic neoplasms that can be immediately applied in practice.
News
Benign Prostatic Hyperplasia
With one of the largest and most experienced urology teams in the region and the latest treatment capabilities, the Fox Chase-Temple Urologic Institute is a trusted leader in treating all types of urologic conditions.
News
Fox Chase-Temple Urologic Institute: The Next Generation of Urology Care
Our innovative partnership unites the expertise of distinguished institutions within one health system, allowing us to tackle the most challenging genitourinary malignancies as well as complex benign urologic conditions.
News
Fox Chase Welcomes Leukemia Specialist Sara Small, MD, PhD
Sara Small, MD, PhD, assistant professor in the Department of Bone Marrow Transplant and Cellular Therapies.
News
TAS1440 +/- All-Trans Retinoic Acid (ATRA) in Relapsed/Refractory AML
A first of its kind, Phase 1 multi-center study for Relapsed or Refractory Acute Myeloid Leukemia using an investigational drug TAS1440 by itself, and in combination with All-Trans Retinoic Acid (ATRA).
News
Key Takeaways from 2023 American Society of Hematology Meeting
Fox Chase Physician Demonstrates Safety and Effectiveness of Myeloma Drug for Black or African American Patients
News
Celebrating 35 years of the Fox Chase-Temple University Hospital Bone Marrow Transplant Program
One of the truly gratifying truths about cancer care is the amazing progress we have made in just the last few decades.